Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $9.00.

A number of research firms have issued reports on PYXS. Royal Bank of Canada reissued an “outperform” rating and set a $8.00 price target on shares of Pyxis Oncology in a research report on Wednesday, March 19th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Pyxis Oncology in a research report on Monday, May 19th.

Institutional Investors Weigh In On Pyxis Oncology

Several institutional investors and hedge funds have recently modified their holdings of PYXS. ProShare Advisors LLC purchased a new stake in shares of Pyxis Oncology in the fourth quarter worth about $26,000. Caption Management LLC purchased a new stake in shares of Pyxis Oncology in the fourth quarter worth about $35,000. Ameriprise Financial Inc. purchased a new stake in shares of Pyxis Oncology in the fourth quarter worth about $35,000. Commonwealth Equity Services LLC boosted its position in shares of Pyxis Oncology by 61.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock worth $41,000 after buying an additional 10,000 shares during the period. Finally, Graham Capital Management L.P. purchased a new stake in shares of Pyxis Oncology in the fourth quarter worth about $47,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Stock Down 1.6%

Shares of NASDAQ:PYXS opened at $1.20 on Monday. The company has a market cap of $74.34 million, a P/E ratio of -1.17 and a beta of 1.18. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.39. The business has a fifty day simple moving average of $1.13 and a 200-day simple moving average of $1.30.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). Sell-side analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.